You are here
Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer.
J Clin Oncol 31, 2013 (suppl; abstr 6507)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Few studies have comprehensively evaluated surgical decisions in young women with breast cancer. Young women have unique medical and psychosocial concerns, and identifying factors associated with surgical choices in this population can inform their decision-making process. Methods: As part of an ongoing multi-center cohort study enrolling women diagnosed with breast cancer at age 40 or younger, we evaluated 277 women with stage I-III disease who indicated they had a choice between mastectomy and breast conserving surgery (BCS). Logistic regression was used to identify predictors of choosing mastectomy vs. BCS. Independent variables with a p-value ≤ 0.15 in bi-variate analyses were included in the final multivariable model. Results: 172/277 women (62%) had either a single or bilateral mastectomy as their definitive surgery. Median age at diagnosis was 37 (range: 17-40). Most women were married (75%), had stage I or II disease (90%), and estrogen receptor (ER) positive tumors (65%); approximately 14% were carriers of a BRCA 1 or 2 mutation. In the multivariable analysis (Table), having a mutation, nodal involvement, HER2-positivity, tumor grade, lower BMI, having 2 or more children, anxiety, and decisional involvement by the patient were all associated with mastectomy. Age, race, marital status, tumor size, having a first degree relative with breast or ovarian cancer, ER status, fear of recurrence, and depression were not significantly associated with having a mastectomy. Conclusions: Despite being candidates for BCS, many young women choose to have a mastectomy. Our results suggest potential targets for interventions such as anxiety reduction and fostering fully informed shared decision-making.
|OR (95% Cl)|
|Mutation positive||10.17 (3.25-31.79)|
|Any nodal involvement||1.88 (1.01-3.52)|
|HER2 positive||2.41 (1.20-4.82)|
|Number of children (ref=0)|
|Decisional involvement (ref=shared)|
|Mainly patient’s decision||2.07 (1.14-3.76)|
|Mainly doctor’s decision||0.86 (0.31-2.38)|
Other Abstracts in this Sub-Category:
Presentations by S. M. Rosenberg :
Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases.
Meeting: 2012 ASCO Annual Meeting
Session: Central Nervous System Tumors(Poster Discussion Session)
Presenter: Minesh P. Mehta
Management of brain metastases in lung cancer patients.
Meeting: 2010 ASCO Annual Meeting
Session: Supportive Care for Patients with Non-small Cell Lung Cancer(Education Session)
Chair: Minesh P. Mehta